Truist analyst Les Sulewski raised the firm’s price target on Pacira (PCRX) to $28 from $25 and keeps a Hold rating on the shares. The firm cites a settlement with eVenus and counterparts for their generic entry of bupivacaine liposome injectable suspension – gExparel – and now envision peak Exparel sales of $740M by 2029, the analyst tells investors in a research note. The deal also removes the much debated overhang, Truist adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- Positive Outlook for Pacira Pharmaceuticals Amid Exparel Settlement and Strategic Growth Initiatives
- Pacira price target raised to $26 from $22 at RBC Capital
- Pacira price target raised to $65 from $48 at H.C. Wainwright
- Closing Bell Movers: Levi Strauss up 8% on earnings, futures find footing
- Pacira Pharmaceuticals Settles Patent Litigation with Fresenius